Literature DB >> 18819824

Hypocretin/orexin disturbances in neurological disorders.

Rolf Fronczek1, Christian Rainer Baumann, Gert Jan Lammers, Claudio Lino Bassetti, Sebastiaan Overeem.   

Abstract

The hypothalamic hypocretin (orexin) system plays a crucial role in the regulation of sleep and wakefulness. The strongest evidence for this is the fact that the primary sleep disorder narcolepsy is caused by disrupted hypocretin signaling in humans as well as various animal models. There is a growing interest in the role of hypocretin defects not only in the pathophysiology of other sleep disorders, but also in neurological diseases with associated sleep symptomatology. In this paper we first review the current methods to measure the integrity of the hypocretin system in human patients. The most widely used technique entails the measurement of hypocretin-1 in lumbar cerebrospinal fluid. In addition, hypocretin levels can be measured in ventricular cerebrospinal fluid and brain tissue extract. Finally, in post-mortem hypothalamic material, the number of hypocretin neurons can be precisely quantified. In the second part of this paper we describe the various neurological disorders in which hypocretin defects have been reported. These include neurodegenerative, neuromuscular and immune-mediated diseases, as well as traumatic brain injury. We conclude with a discussion of the functional relevance of partial hypocretin defects, and the various pathophysiological mechanisms that can lead to such defects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18819824     DOI: 10.1016/j.smrv.2008.05.002

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  10 in total

Review 1.  Sleep neurobiology from a clinical perspective.

Authors:  Rodrigo A España; Thomas E Scammell
Journal:  Sleep       Date:  2011-07-01       Impact factor: 5.849

2.  Progressive changes of orexin system in a rat model of 6-hydroxydopamine-induced Parkinson's disease.

Authors:  Long-Biao Cui; Bo-Wei Li; Xiao-Hang Jin; Lin Zhao; Juan Shi
Journal:  Neurosci Bull       Date:  2010-10       Impact factor: 5.203

Review 3.  Sleep disorders, obesity, and aging: the role of orexin.

Authors:  Joshua P Nixon; Vijayakumar Mavanji; Tammy A Butterick; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Ageing Res Rev       Date:  2014-11-22       Impact factor: 10.895

4.  Orexin/hypocretin treatment restores hippocampal-dependent memory in orexin-deficient mice.

Authors:  Vijayakumar Mavanji; Tammy A Butterick; Cayla M Duffy; Joshua P Nixon; Charles J Billington; Catherine M Kotz
Journal:  Neurobiol Learn Mem       Date:  2017-10-28       Impact factor: 2.877

Review 5.  Narcolepsy: neural mechanisms of sleepiness and cataplexy.

Authors:  Christian R Burgess; Thomas E Scammell
Journal:  J Neurosci       Date:  2012-09-05       Impact factor: 6.167

Review 6.  Intranasal insulin and orexins to treat age-related cognitive decline.

Authors:  Jennifer M Erichsen; Coleman B Calva; Lawrence P Reagan; Jim R Fadel
Journal:  Physiol Behav       Date:  2021-02-21

Review 7.  Metabolic signals in sleep regulation: recent insights.

Authors:  Charu Shukla; Radhika Basheer
Journal:  Nat Sci Sleep       Date:  2016-01-05

8.  Dexamethasone Chemotherapy Does Not Disrupt Orexin Signaling.

Authors:  David E Kram; Stephanie M Krasnow; Peter R Levasseur; Xinxia Zhu; Linda C Stork; Daniel L Marks
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

9.  Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson's disease.

Authors:  Agathe Bridoux; Stephane Moutereau; Ala Covali-Noroc; Laurent Margarit; Stephane Palfi; Jean-Paul Nguyen; Jean-Pascal Lefaucheur; Pierre Césaro; Marie-Pia d'Ortho; Xavier Drouot
Journal:  Nat Sci Sleep       Date:  2013-06-12

10.  Molecular Evolutionary Analysis of the HCRTR Gene Family in Vertebrates.

Authors:  Zhen Cai; Hehe Liu; Liyun Wang; Xinxin Li; Lili Bai; Xinmeng Gan; Liang Li; Chunchun Han
Journal:  Biomed Res Int       Date:  2018-06-04       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.